title: Combination use of ustekinumab with other systemic therapies: a retrospective study in a tertiary referral center.
abstract: BACKGROUND
  Patients with moderate to severe psoriasis may not respond adequately to single systemic agent and may require combination systemic therapy.
  
  
  OBJECTIVE
  To evaluate the prevalence, indications, and response to combination systemic therapy with ustekinumab for psoriasis in a tertiary referral center.
  
  
  METHODS
  This retrospective study comprised 102 psoriasis patients treated with ustekinumab at a single tertiary care center. Data was collected pertaining to history of psoriasis, past and current therapies including use of concomitant psoriasis agents, response to therapy, and side effects while on ustekinumab.
  
  
  RESULTS
  Twenty-two of 102 (22%) patients were identified as receiving combination systemic treatment involving ustekinumab and at least one additional agent. The most common indication for combination therapy was psoriatic arthritis (35%), followed by bridging therapy (26%), inadequate psoriasis control (13%), prevention of non-melanoma skin cancers (17%), and control of palmoplantar disease (9%). Methotrexate was the additional agent in 12 patients, cyclosporine in 7 patients, acitretin in 5 patients, and 1 patient received a second biologic agent, first etanercept and then adalimumab. Overall, the reduction in body surface area (BSA) was 80% for patients on combination therapy. For those patients on combination therapy for psoriatic arthritis, 75% had resolution or stabilization of their symptoms. Only one patient, receiving cyclosporine, discontinued combination therapy due to adverse side effects.
  
  
  CONCLUSIONS
  Combination systemic therapy with ustekinumab can be effective and well tolerated for patients who cannot be adequately treated with ustekinumab alone.
authors.forename: Gillian M
authors.initials: GM
authors.lastname: Heinecke
authors.forename: Adam J
authors.initials: AJ
authors.lastname: Luber
authors.forename: Jacob O
authors.initials: JO
authors.lastname: Levitt
authors.forename: Mark G
authors.initials: MG
authors.lastname: Lebwohl
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D001688:Biological Products / Q000627:therapeutic use; D016572:Cyclosporine / Q000008:administration & dosage / Q000627:therapeutic use; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000627:therapeutic use; D008875:Middle Aged; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy*; D012176:Retinoids / Q000627:therapeutic use; D012189:Retrospective Studies; D062606:Tertiary Care Centers; D000069549:Ustekinumab
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D003879:Dermatologic Agents; D007166:Immunosuppressive Agents; D012176:Retinoids; D016572:Cyclosporine; D000069549:Ustekinumab; D008727:Methotrexate